As GLP-1 agonists like Ozempic and Mounjaro shift from niche treatments to clinical staples, a pragmatic question has emerged for taxpayers: can these significant monthly expenses be deducted? In Brazil, the Receita Federal maintains a rigid boundary that often surprises those managing chronic conditions. Despite the medical necessity and the requirement of a formal prescription, pharmacy-bought medications remain ineligible for tax relief.
The distinction lies in the point of sale rather than the drug’s therapeutic value. According to Sumaya Mangini, a tax specialist at KPMG, the general rule is uncompromising: medications purchased for home use do not qualify as deductible health expenses. This applies regardless of whether the treatment is continuous or life-saving. In the eyes of the tax authority, these "weight-loss pens" are treated no differently than standard pharmacy goods once they leave a commercial shelf; they are considered private consumption rather than a deductible medical service.
There is, however, a narrow administrative window for deduction. Charles Gularte, an executive at Contabilizei, notes that medications only become deductible when they are integrated into a hospital or clinic’s billing. If a drug is administered during a surgical procedure or a period of hospitalization and appears explicitly on the facility’s invoice, it is reclassified as a "hospital expense." For the vast majority of users self-administering these drugs at home, this exception remains out of reach, leaving the financial burden of the GLP-1 revolution squarely on the consumer.
With reporting from InfoMoney.
Source · InfoMoney
